SANABIT represents one of the most distinctive chapters of Joseph Fargnoli’s career as an innovation leader — the application of rigorous engineering discipline to one of humanity’s most fundamental needs: healing. As founder of SANABIT, Fargnoli has spent over a decade advancing a patented, non-invasive approach to accelerating the body’s own recovery mechanisms, without drugs, without incisions, and without chemicals.
SANABIT’s devices work by applying safe, precisely calibrated magnetic fields to targeted tissue, stimulating the mitochondria inside cells to operate more efficiently. More efficient mitochondria means more cellular energy available for repair — and faster repair means faster recovery. The underlying biology is well-established; what SANABIT has developed is a practical, device-based method for activating it deliberately and non-invasively. The company’s patented and patent-pending innovations reflects years of early breakthrough research now being translated toward real-world clinical application, with a product scope that intentionally spans both human medicine and veterinary care.
On the surface, a career built on imaging systems and national security engineering programs doesn’t obviously lead to founding a medical device company. For Fargnoli, the link is direct. The discipline required to build complex, high-stakes systems — the methodical approach to problem decomposition, the insistence on translating scientific principle into scalable, practical output — applies just as cleanly to the challenge of accelerating human healing as it does to the challenge of imaging the Earth from orbit.
Fargnoli founded SANABIT in 2015, bringing that same systems-level rigor to a domain where the stakes are unmistakably personal. His background in electro-optical systems, advanced computing, and AI engineering gave him a vantage point for medical device development that is uncommon in the field: technically rigorous, outcome-focused, and grounded in the conviction that engineering’s highest purpose is to reduce suffering and expand human possibility. As founder, he has guided the company’s core research direction, its partnerships with leading academic institutions, and its commitment to developing products that are as safe and accessible as they are effective. That commitment is, in Fargnoli’s own framing, an expression of something larger — his belief that innovation advances human well-being not by increasing our power, but by enlarging our compassion.
Founded in 2015 and based in the Rochester, New York metropolitan area, SANABIT is committed to translating early breakthrough research into effective, accessible products for a wide range of medical applications in both humans and animals. The company’s devices are non-invasive and non-chemical, designed for patient safety and broad clinical applicability. Learn more at sanabit.org.